SEIKAGAKU CORPORATION Logo

SEIKAGAKU CORPORATION

A research pharma company using glycoscience to develop drugs for orthopedic & ophthalmic diseases.

4548 | T

Overview

Corporate Details

ISIN(s):
JP3414000004
LEI:
Country:
Japan
Address:
千代田区丸の内一丁目6番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Seikagaku Corporation is a research-driven pharmaceutical company specializing in glycoscience. The company engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices, with a primary focus on glycoconjugates like glycosaminoglycans (GAGs). Its main therapeutic areas include orthopedic disorders and ophthalmic diseases, offering products such as joint function improving agents. Seikagaku oversees its product lifecycle from in-house drug discovery and clinical trials to regulatory approval and commercial production, leveraging its specialized expertise in the field of complex carbohydrates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 06:56
Registration Form
確認書
Japanese 8.1 KB
2025-11-12 06:55
Interim Report
半期報告書-第80期(2025/04/01-2026/03/31)
Japanese 196.8 KB
2025-06-24 08:14
Post-Annual General Meeting Information
臨時報告書
Japanese 23.0 KB
2025-06-23 06:58
Governance Information
内部統制報告書-第79期(2024/04/01-2025/03/31)
Japanese 22.6 KB
2025-06-23 06:57
Registration Form
確認書
Japanese 8.0 KB
2025-06-23 06:56
Annual Report
有価証券報告書-第79期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2024-11-12 06:58
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-12 06:56
Interim Report
半期報告書-第79期(2024/04/01-2025/03/31)
Japanese 191.1 KB
2024-06-27 06:53
Governance Information
内部統制報告書-第78期(2023/04/01-2024/03/31)
Japanese 21.9 KB
2024-06-27 06:52
Registration Form
確認書
Japanese 8.0 KB
2024-06-27 06:51
Annual Report
有価証券報告書-第78期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-06-25 04:10
Post-Annual General Meeting Information
臨時報告書
Japanese 23.7 KB
2024-02-14 08:57
Quarterly Report
四半期報告書-第78期第3四半期(2023/10/01-2023/12/31)
Japanese 165.1 KB
2024-02-14 08:57
Report Publication Announcement
確認書
Japanese 8.0 KB
2023-11-14 05:06
Report Publication Announcement
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all SEIKAGAKU CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SEIKAGAKU CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SEIKAGAKU CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Biotest AG Logo
Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.
Germany
BIO3
Biotika A.S. Logo
Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.
Slovakia
BSL
Bioton S.A. Logo
Develops and manufactures recombinant human insulin for global diabetes care solutions.
Poland
BIO
BIOVENTIX PLC Logo
Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.
United Kingdom
BVXP
Bioversys N Logo
Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.
Switzerland
BIOV
Biovica International B Logo
Develops blood tests to monitor the efficacy of solid tumor cancer therapies.
Sweden
BIOVIC
BIOVIE INC. Logo
Develops drug therapies for Alzheimer's, Parkinson's, and advanced liver diseases by targeting inflammation.
United States of America
BIVI
BioXcel Therapeutics, Inc. Logo
AI-driven biopharma developing treatments for neuroscience and immuno-oncology.
United States of America
BTAI
Black Diamond Therapeutics, Inc. Logo
Develops precision oncology drugs targeting mutation families in lung and brain cancers.
United States of America
BDTX
BL Pharmtech Corp. Logo
Manufactures and distributes health foods, supplements, and cosmetics with bio-pharmaceutical R&D.
South Korea
065170

Talk to a Data Expert

Have a question? We'll get back to you promptly.